Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immune hemolytic anemia--selected topics.

Philip C Hoffman1

  • 1University of Chicago, 5841 S Maryland Ave, MC2115, Chicago, IL 60637, USA. phoffman@medicine.bsd.uchicago.edu

Hematology. American Society of Hematology. Education Program
|November 25, 2006
PubMed
Summary

Autoimmune hemolytic anemia (AIHA) can occur with certain cancer treatments and transplants. Newer therapies like rituximab offer effective options for difficult AIHA cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Carboplatin, gemcitabine, and mifepristone for advanced breast and recurrent/persistent epithelial ovarian cancer.

Breast cancer research and treatment·2025
Same author

Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression.

Clinical lung cancer·2023
Same author

Serving on the FDA oncologic drugs advisory committee.

Clinical advances in hematology & oncology : H&O·2022
Same author

CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer.

Scientific reports·2021
Same author

A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2021
Same author

Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.

Breast cancer research and treatment·2020

Area of Science:

  • Hematology
  • Immunology
  • Transplantation

Background:

  • Autoimmune hemolytic anemia (AIHA) is often idiopathic but increasingly recognized with purine analog therapy for hematologic malignancies.
  • AIHA is a complication of alloimmunization and ABO-incompatible transfusions, hematopoietic stem cell transplants, and solid organ transplants.
  • Venous thromboembolism and lymphoproliferative disorders are potential complications of AIHA.

Purpose of the Study:

  • To review the associations and complications of autoimmune hemolytic anemia (AIHA).
  • To discuss emerging treatment options for refractory AIHA.

Main Methods:

  • Literature review of AIHA associations, complications, and treatments.
  • Analysis of recent clinical experiences with novel therapies.

Main Results:

  • AIHA incidence is rising with purine analogs and in transplant recipients.
  • Venous thromboembolism and lymphoproliferative disorders are recognized complications.
  • Mycophenolate and rituximab show promise for refractory AIHA.

Conclusions:

  • AIHA has diverse associations and complications beyond its idiopathic form.
  • Novel immunosuppressives and monoclonal antibody therapy represent effective treatment strategies for refractory AIHA.

Related Experiment Videos